Identifying Common Treatment Recommendations in Clear Cell Renal Cell Carcinoma

Share this content:

the Cancer Therapy Advisor take:

Heterogeneity of decision criteria was observed in most clinical scenarios comparing treatment algorithms in the treatment of metastatic clear cell renal cell carcinoma (mccRCC), according to an article published online in the journal The Oncologist.

The authors of this study aimed to obtain treatment algorithms and develop decision trees through the analysis of treatment of mccRCC from experts at 11 institutions.

Results showed the most common treatment recommendations for mccRCC included sunitinib, pazopanib, temsirolimus, interferon-α combined with bevacizumab, high-dose interleukin-2, sorafenib, axitinib, everolimus, and best supportive care. 

Furthermore, the criteria relevant for treatment decision-making included performance status, Memorial Sloan-Kettering Cancer Center risk group, only or mainly lung metastases, cardiac insufficiency, hepatic insufficiency, age, and “zugzwang” (composite of multiple, related criteria).

The study’s findings demonstrate how available data, regarding decision criteria and different treatment strategies, are implemented distinctly among experts.

For high-risk, localized prostate cancer, adjuvant chemotherapy improved the overall survival from 8
Heterogeneity of decision criteria was observed in most clinical scenarios in treatment of metastatic clear cell renal cell carcinoma.
Heterogeneity of decision criteria was observed in most clinical scenarios comparing treatment algorithms in the treatment of metastatic clear cell renal cell carcinoma (mccRCC).
READ FULL ARTICLE From theoncologist.alphamedpress.org

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs